For the quarter ending 2026-03-31, ENSC made $960,999 in revenue. -$3,556,415 in net income. Net profit margin of -370.07%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Federal grants | 960,999 | 1,882,336 | 493,104 | 1,371,438 |
| Research and development | 3,346,881 | 3,613,028 | 2,954,909 | 1,923,430 |
| General and administrative | 1,176,348 | 1,051,132 | 1,279,290 | 1,198,523 |
| Total operating expenses | 4,523,229 | 4,664,160 | 4,234,199 | 3,121,953 |
| Loss from operations | -3,562,230 | -2,781,824 | -3,741,095 | -1,750,515 |
| Change in fair value of liability classified warrants | - | 35 | 998 | -853 |
| Interest expense, net | 3,923 | 5,382 | 6,369 | 3,160 |
| Other income and expense, net | 9,738 | 19,202 | 17,338 | 21,011 |
| Total other income (expense), net | 5,815 | 13,855 | 11,967 | 16,998 |
| Net loss | -3,556,415 | -2,767,969 | -3,729,128 | -1,733,517 |
| Deemed dividend related to warrants down round provision | - | - | - | 0 |
| Net gain attributable to noncontrolling interests | - | -321 | - | -166 |
| Net loss attributable to common stockholders | -3,556,415 | -2,767,648 | -3,729,128 | -1,733,351 |
| Basic EPS | -0.52 | -1.082 | -1.29 | -0.79 |
| Diluted EPS | -0.52 | -1.082 | -1.29 | -0.79 |
| Basic Average Shares | 6,839,385 | 2,557,377* | 2,886,059 | 2,202,299 |
| Diluted Average Shares | 6,839,385 | 2,557,377* | 2,886,059 | 2,202,299 |
Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc. (ENSC)